SEC Comment Letter 0000000000-23-001003 to XORTX Therapeutics Inc. (XRTX) (CIK 0001729214) (XRTX)
XORTX Therapeutics Inc. (XRTX) (CIK 0001729214)
Date: Jan. 31, 2023 · CIK: 0001729214 · Accession: 0000000000-23-001003
AI Filing Summary & Sentiment
File numbers found in text: 333-269429
Letter
United States securities and exchange commission logo January 31, 2023 Allen Davidoff Chief Executive Officer XORTX Therapeutics Inc. 3710 — 33rd Street NW Calgary, Alberta, Canada Re:XORTX Therapeutics Inc. Registration Statement on Form F-3 Filed January 27, 2023 File No. 333-269429 Dear Allen Davidoff: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Thomas Rose
Show Raw Text
United States securities and exchange commission logo
January 31, 2023
Allen Davidoff
Chief Executive Officer
XORTX Therapeutics Inc.
3710 — 33rd Street NW
Calgary, Alberta, Canada
Re:XORTX Therapeutics Inc.
Registration Statement on Form F-3
Filed January 27, 2023
File No. 333-269429
Dear Allen Davidoff:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Thomas Rose